AAV & Plasmids (Program Design to GMP)

Scope: AAV vector design and manufacturing (capsid/promoter/payload), production in adherent, suspension, or fixed-bed platforms; producer-line or transient workflows; chromatography-based and charge-based empty/full control; plasmid DNA supply from research through GMP; analytics, stability, fill–finish, and submission-ready documentation—all within a unified digital QMS (ALCOA+).

AAV programs succeed when the biological design, the physical process, and the documentary record are aligned from day one. We take a conservative, engineering-first approach: define what the dose must be and how it will be verified; choose an architecture that supports that outcome; then implement upstream, downstream, and analytical methods that operators can repeat and auditors can follow. Plasmid supply is treated as a first-class dependency, not a procurement line—topology, residuals, and consistency are engineered into the process, not inspected in after the fact.

Why teams run AAV & pDNA here

A vector is more than a titer. It is a specific genome inside a specific capsid, with a defined distribution of empty and full particles, delivered in a buffer that preserves function and safety. The simplest way to achieve that reliably is to constrain decisions early and measure the right things at the right time.

• End-to-end ownership. Vector design, plasmid supply, upstream (adherent/suspension/fixed-bed), downstream (capture/polish/empty-full/TFF), analytics, fill–finish, and stability—implemented consistently across both hubs under one QMS.
• Evidence-based process selection. Transient transfection when agility and timeline dominate; producer lines when consistency, throughput, or economics justify the investment. We document the tradeoffs in plain language and commit to a path.
• Orthogonal analytics by default. Primary methods are paired with confirmations where they materially reduce risk (e.g., charge-based empty/full plus an orthogonal confirmation appropriate to phase).
• Operator-holdable settings. Ranges and interlocks reflect what can be run at scale without drama. If a step can’t be held by trained staff on a night shift, it’s not ready.

Background: AAV design and manufacturing constraints that actually matter

Most avoidable failures trace back to four themes: payload architecture that pushes packaging limits; production conditions that don’t translate to scale; purification strategies that look promising on a gradient but not at volume; and analytical stacks that are insufficiently orthogonal. We address those upstream. Payload size and cassette design are treated as process parameters. Residence time, shear, and mass transfer are modeled realistically. Empty/full separation is planned as a production operation, not a one-off experiment. And analytics are specified with clear acceptance criteria before development starts.

Program spine: QTPP → CQAs → CPPs

Before work begins, we write down what “good” means and how it will be demonstrated.

QTPP (intended product): route (IV/IM), dose, presentation (vial or prefilled syringe), target shelf life, acceptable levels for residual DNA/protein/nuclease/detergents, acceptable empty/full window, sterility and endotoxin limits, and osmolality/pH constraints.

CQAs (measured attributes): vector genome titer (qPCR/ddPCR), total capsid, empty/full ratio by a primary method plus orthogonal confirmation as phase warrants, potency (cell-based transduction or function), residuals (host DNA/host protein/plasmid traces/nucleases/detergents), sterility, endotoxin, mycoplasma (as applicable), and for plasmids: topology (SC/OC/L), residual RNA/gDNA, protein, and endotoxin.

CPPs (controlled levers): cassette design (promoter/UTR/polyA), payload size, production mode (adherent/suspension/fixed-bed; transient vs producer line), media and feed controls, transfection or induction parameters, pH/DO/mixing and shear windows, capture binding and residence times, polishing gradients/ionic strength, nuclease conditions, TFF transmembrane pressure and cross-flow, and fill-finish parameters including filtration ∆P/T and nitrogen overlay if required.

The control strategy that links these is placed in protocols and batch records up front; it’s not retrofitted after development.

Vector architecture & payload design

A careful design phase eliminates a surprising amount of downstream complexity.

• Capsid selection and brief. We document tropism, pre-existing immunity considerations, manufacturing behavior (yield and empty propensity), and known polishing sensitivities.
• Expression cassette. Promoter/enhancer choice, introns, UTRs, and polyA are balanced for potency at size; over-pack risk is explicitly evaluated.
• Payload sizing and guardrails. We quantify the risk of truncation or partial packaging and adopt limits that protect the target empty/full window and potency readouts.
• Manufacturability checkpoints. We assess how cassette design influences downstream interactions (e.g., nuclease dependence, buffer vulnerability).

Production platforms

Platform choice is constrained by scale, quality targets, and facility fit. We lay out the options and select deliberately.

• Adherent. Appropriate for early programs; fixed-bed systems can extend the useful range. We protect against diffusion constraints and plan for realistic cleaning and sampling.
• Suspension. Preferred for larger scales; we manage pH/DO and shear without defaulting to conditions that compromise quality.
• Fixed-bed. Useful for certain cell lines and space-limited builds; we plan around mass transfer, residence time, and harvest logistics.
• Transient vs producer line. Transient provides agility; producer lines can deliver consistency and cost advantages later. We define success criteria and make the change with a comparability protocol when warranted.
• Perfusion. Considered when residence time or productivity gains justify increased operational complexity; cleaning and validation implications are addressed up front.

Upstream development: control oxygen, shear, and variability

Upstream outcomes are predictable when physics is respected.

• Seed trains. Sized for turnaround and contamination risk; bank usage controlled in the QMS.
• Transfection (if transient). Reagent stoichiometry, osmolality, media exchanges, and mixing plans are tuned for scale; we avoid local extremes that drive variability.
• Operational envelopes. pH/DO/mixing and temperature windows are set by data, not convention. We track viability and productivity against these windows in real time.
• PAT. Off-gas, capacitance, and spectroscopic signals are calibrated to reference assays so daily decisions are defensible.

Downstream: capture, polishing, empty/full, and buffer exchange

We design the purification train to survive production, not just a demo.

• Clarification and nuclease. We condition harvests for consistent filter performance; nuclease steps are sized for DNA load and verified with residual testing.
• Primary capture. Affinity or charge-first strategies are chosen based on capacity, cleanability, and lifecycle cost; breakthrough and cleaning are measured on real material.
• Polishing. Ion-exchange or mixed-mode steps are tuned to the impurity map; gradients and steps are documented for operator reality.
• Empty/full separation. Charge-based approaches are optimized for lot-to-lot stability; orthogonal confirmation is used according to phase to avoid self-deception.
• TFF and buffer exchange. Membrane choice and recipe protect potency and aggregation behavior; osmolality and pH are locked for presentation and device compatibility.

Each step carries a mass balance and recovery record; filter and resin lifecycles are tracked by lot and cycle count.

Analytics: a stack that answers the real questions

A concise, orthogonal panel provides clarity without excess.

• AAV core panel. vg titer (qPCR/ddPCR); capsid quantitation; empty/full ratio (primary + orthogonal confirmation as phase requires); potency aligned to mechanism; residual DNA/protein/nuclease/detergents; sterility, endotoxin, and mycoplasma where applicable.
• Vector identity and integrity. Cassette confirmation methods appropriate to phase; precautions against inhibition in qPCR/ddPCR; controls that detect drift.
• In-process control. Readouts positioned where they inform decisions (e.g., nuclease effectiveness, capture loading, polishing clearance, TFF recovery).
• Trending. Control charts for empty/full, residuals, and potency; predeclared actions for drift and outliers.
• Plasmid analytics. Identity by mapping or sequencing when justified; topology (SC/OC/L), residual RNA/gDNA, protein, and endotoxin.

Methods move through development → transfer → qualification/validation with documented acceptance criteria and change control.

Plasmid DNA (pDNA): supply that won’t compromise the vector

Plasmids are central to transient production and still matter with producer lines (for cell line construction and changes). We run pDNA like a product, not a reagent.

• Host and fermentation. Carbon-limited fed-batch avoids overflow metabolism and proteolysis; oxygen transfer is sized realistically for scale.
• Alkaline lysis & clarification. Conditions are tuned for viscosity and RNA control; shear budgets are respected.
• Capture and polish. AEX capture sized for supercoiled content and endotoxin control; subsequent steps protect topology while clearing residuals.
• Formulation and presentation. Buffers support transfection or line construction; sterile filtration feasibility and hold times are empirically determined.
• QC. Topology distribution, residuals, identity, and endotoxin; suitability readouts where they materially reduce risk.

Fill–finish and presentation

Drug product operations are defined by what protects function and meets site needs.

• Buffers and excipients. Chosen for potency preservation, osmolality, and device compatibility; we avoid unnecessary components.
• Sterile filtration feasibility. Demonstrated on real bulk with recovery and integrity measured; if filtration undermines function, we use aseptic processing with validated controls.
• Presentation. Vials or prefilled syringes; nitrogen overlay where oxidation is a concern; clear, enforceable hold times.
• Inspection and CCIT. Processes and methods are validated for the selected container closure; sampling plans are statistical, not symbolic.

Stability programs

Stability design reflects actual logistics rather than generic templates.

• Design. Real and accelerated conditions; stress studies that map relevant degradation pathways; osmolality and potency retention for vectors are emphasized.
• Readouts. Empty/full stability (where informative), potency, residuals, and visual/particulate criteria; for pDNA, topology stability and residual profiles.
• Shelf-life rationale. Assigned from data and reviewed periodically; any lane or device change triggers a targeted study and comparability where required.

Validation, PPQ, and lifecycle

Validation packages are organized around clarity and reproducibility.

• Design space to recipe. Development ranges are translated into batch records; interlocks and alarms are meaningful.
• Viral clearance and hold-time studies. Executed as appropriate to phase; studies are sized to answer specific questions.
• Media fills/process simulations. Representative interventions and worst-case holds are incorporated; results are trended across runs.
• Cleaning validation. Surfaces, soils, and MACO/PDE logic are documented; periodic verification is scheduled and executed.

Facilities & scale

Capabilities are sized to common program needs and documented transparently.

• Production. Adherent, suspension, and fixed-bed footprints; perfusion options where justified; closed-system capability.
• Cleanrooms. ISO 8/7 with positive flows; BSL-2 where required; utilities (HPW/clean steam/compressed air) validated and trended.
• Purification. Pilot to GMP chromatography and TFF skids; viral filtration where applicable; recipe control with qualified sensors.
• Analytics. qPCR/ddPCR; HPLC/UPLC; CE-SDS; icIEF; DLS/osmolality; phase-appropriate tools for empty/full confirmation.
• Digital systems. Validated CDS, LIMS, ELN, and eBMR/eBR with audit trails and controlled access.

Regulatory and QMS posture

The file should read like a straightforward narrative: what the product is, how it’s made, how it is measured, and how sameness is demonstrated when changes occur.

• QbD. The control strategy is explicit and present in protocols and batch records.
• Digital QMS. Deviation/CAPA, change control, investigations, training—one spine across both hubs.
• Authoring. CMC sections reflect actual methods and data; reviewer questions are answered with tables and statistics plans, not adjectives.
• Comparability. Protocols are prespecified for site, scale, or material changes; acceptance windows and orthogonal confirmations are planned.

Program onboarding (first 30 days)

The first month is structured to remove ambiguity and prevent rework.

1. Control strategy mapped from QTPP to CQAs to CPPs for AAV and/or pDNA.
2. DoE plan covering production (adherent/suspension/fixed-bed; transient/producer), capture/polish/empty-full/TFF, and the analytical stack with sampling plans and acceptance criteria.
3. Gantt and risk register with decision gates to IND/registration; a plasmid supply plan and a fill-finish feasibility outline.

We request your latest data (design, titer history, residuals, stability, deviations) and return a written plan with dates and criteria.

Indicative timelines (biology-gated)

• Feasibility. Capsid/cassette brief; early production test; capture/polish screen; plasmid feasibility (yield/topology).
• Development. Upstream DoE; downstream recovery and impurity clearance; empty/full separation; analytics stack qualified; filtration feasibility.
• Engineering. Scale-similar mixing and hydrodynamics; mass balance and trending; stability enrollment; documentation package drafted.
• Lock. Process description with CPP ranges; validation plans; comparability where needed.

We state gates and pass criteria; biological reality sets the pace.

Tech transfer and remediation

When programs arrive mid-stream, we stabilize first and then optimize.

• Triage. Methods, deviations, stability, change controls, resin/filter lifecycles; for vectors, empty/full instability and nuclease residuals; for pDNA, topology loss during TFF.
• Gap mapping. Which CQAs lack controls; which CPPs drift; which fixes buy the most risk reduction fastest.
• Stabilize → optimize → re-lock. Interim setpoints to stop failures; targeted DoE for the true drivers; comparability to bridge changes; lifecycle files updated.

Deliverables

The following artifacts are produced and controlled:

• Control strategy and process description with CPP ranges.
• AAV package: mass balance, recovery, impurity clearance; empty/full plan and results; TFF recipe and hold-time evidence.
• pDNA dossier: bank identity, yield, topology, residuals; capture/polish performance.
• Analytics files: methods, transfer, qualification/validation, trending.
• Fill–finish files: filtration recovery/integrity, settings, inspection and CCIT plans.
• Stability protocols/data with a defendable shelf-life rationale.
• Batch records (eBMR/eBR) and CMC text ready for submission.

Frequently asked

Do you support both adherent and suspension AAV?

Yes; fixed-bed is available where it fits. Mode is selected based on scale, quality targets, and operations.

How do you confirm empty/full?

Charge-based separation paired with an orthogonal confirmation appropriate to phase; acceptance windows are prespecified.

Producer line or transient?

We start transient when speed matters; we adopt producer lines when the economics and consistency justify, with a comparability plan.

Can pDNA be supplied at GMP?

Yes—research through GMP with topology and residuals controlled; buffers and presentation suited to your process.

What if sterile filtration reduces potency?

We either redesign for filterable properties or run validated aseptic operations; the decision and controls are documented.

Summary

This modality page reflects a straightforward approach: define the product, control the physics, measure what matters, and document each link. AAV vectors and plasmids produced under this discipline are consistent at scale and defensible at inspection. If you want the next steps laid out for your program, send current data and we will return a plan with explicit gates and criteria.

Talk to our team today → email info@mycovistabiotech.com